The ban has not been totally lifted but it is only a partial lifting of the ban. The reason is the rapid spread of the Coronavirus at an alarming pace in the US. The FDA realized that since Chloroquine tablets can act as a cure for Coronavirus, they would need adequate supply of these tablets. That is the reason the FDA has partially lifted the ban on the manufacture of Chloroquine tablets by IPCA Laboratories. This is only a partially lifting of the ban and it is also temporary. The medicine is considered one of the possible treatments for the infection, officially called Covid-19. US FDA has permitted the import of active pharmaceutical ingredients (APIs) of hydroxychloroquine sulphate and chloroquine phosphate produced at IPCA's APl manufacturing unit at Ratlam. However, US FDA has clarified that this is purely temporary and that such exceptions would be re-considered if the shortage situation ceases. The plant has been under import alert for over 3 years for multiple violations of good manufacturing practices. There are nearly 20,000 people in the US who have been infected by the virus and more than 100 have died.